Clinical trial Recruiting at 4 sites Phase 3 Interventional Ages 18 to 60

Collecting stem cells from healthy unrelated donors using filgrastim

Official title: Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors

Run by Center for International Blood and Marrow Transplant Research · NCT00785525 · Data updated 2026-11-12

This study is testing a way to safely collect stem cells from healthy volunteers using a medication called filgrastim to see if it can help make more stem cells available for people needing transplants.

More Healthy Aging trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment60000 (estimated)
SponsorCenter for International Blood and Marrow Transplant Research
Research network
Locations4 sites (Boca Raton, Florida and 3 other locations)
StatusRecruiting
StartedFebruary 1997
Main results expectedJanuary 2030
Study endsJanuary 2030
Registry record updatedApril 13, 2025
Trial IDNCT00785525 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are healthy individuals who are willing to donate stem cells and meet the eligibility criteria set by the National Marrow Donor Program.

Probably not a fit

Patients who are pregnant, breastfeeding, or have certain medical histories such as autoimmune disorders or previous thromboembolic events may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish a system for collecting filgrastim-mobilized peripheral blood stem cells (PBSC) from unrelated donors registered with the National Marrow Donor Program. It evaluates the safety of filgrastim administration and the leukapheresis process among these donors, as well as the safety and efficacy of the collected PBSC in transplant recipients. The study also seeks to determine how acceptable the donation process is for healthy individuals. By leveraging a large donor registry, the study hopes to enhance the availability of stem cells for transplantation.

Why it matters

Potential benefit: If successful, this study could improve the safety and efficacy of stem cell transplants from unrelated donors, potentially saving more lives.

How similar studies have gone: Previous studies have shown success in using filgrastim for mobilizing stem cells, making this approach well-supported by existing evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. PBSC donors must meet the same criteria as NMDP marrow donors. These criteria are set forth in the Donor Center Manual of Operations.
2. Confirmatory pregnancy test must be performed within 15 days of collection and prior to the start of filgrastim administration; this may require more than one test to be performed.

Exclusion Criteria:

1. Pregnancy or uninterruptible breastfeeding. Pregnancy is an absolute contraindication under this protocol. Women who are breastfeeding must be willing and able to interrupt breastfeeding during the administration of filgrastim and for two days following the final dose.
2. Sensitivity to filgrastim or to E. coli-derived recombinant protein products.
3. History of autoimmune disorders, including rheumatic diseases and thyroid disorders. Exception: As with bone marrow donations, donors with a history of thyroid disease who have undergone successful therapy may be suitable.
4. History of deep vein thrombosis or pulmonary embolism.
5. History of iritis or episcleritis.
6. Thrombocytopenia \< 150 x 10\^9/L (\< 150,000/uL) at baseline evaluation.
7. Current treatment with lithium. Drug interactions between filgrastim and lithium, which may potentiate the release of neutrophils, have not been fully evaluated.
8. Positive Hemoglobin-Solubility (e.g., SickleDex or equivalent) test.
9. Donors receiving experimental therapy or investigational agents.
10. Positive pregnancy test collected/reported prior to start of filgrastim.

Where it's running

  • Gift of Life Bone Marrow Foundation
    Boca Raton, Florida, United States
    Recruiting
  • C.W. Bill Young Marrow Donor Center
    Rockville, Maryland, United States
    Recruiting
  • Be The Match
    Minneapolis, Minnesota, United States
    Recruiting
  • DKMS Americas
    New York, New York, United States
    Recruiting

Study contacts

  • Principal investigator: John P Miller, MD, PhD — National Marrow Donor Program
  • Study coordinator: Lisa Erickson
  • Email: PBSCStudyTeam@nmdp.org

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.